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ABSTRACT
Genome-wide experimental methods to identify disease
genes, such as linkage analysis and association
studies, generate increasingly large candidate gene
sets for which comprehensive empirical analysis is
impractical. Computational methods employ data from
a variety of sources to identify the most likely candidate
disease genes from these gene sets. Here, we review
seven independent computational disease gene prior-
itization methods, and then apply them in concert to the
analysis of 9556 positional candidate genes for type 2
diabetes (T2D) and the related trait obesity. We generate
and analyse a list of nine primary candidate genes for
T2D genes and five for obesity. Two genes, LPL and
BCKDHA, are common to these two sets. We also
present a set of secondary candidates for T2D
(94 genes) and for obesity (116 genes) with 58 genes
in common to both diseases.
INTRODUCTION
Genome-wide empirical studies generate large sets of poten-
tial candidate genes. However, it remains difficult to identify
the most likely disease-related genes. In this study, we review
existing computational methods for disease gene identifica-
tion and describe their differences and similarities, and then
we apply these methods in a complementary fashion to the
identification of candidate disease genes for the complex dis-
ease type 2 diabetes (T2D) and the related trait obesity. Our
aim is to offer the prospective user an overview of the inputs,
outputs and functionality of the methods, to illustrate the use
of these methods applied to a single problem, and to present a
new set of most likely candidate disease genes for the com-
plex diseases T2D and obesity.
Familial studies indicate that many diseases are caused by
ectopic loss or gain of gene function, and research to date has
identified numerous genes implicated in simple (Mendelian)
diseases. Existing methods have been successful in identify-
ing single high relative risk disease genes, but have typically
failed to identify genes underlying complex diseases or traits
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that often present with a wide range of phenotypes and
generally involve multiple aetiological mechanisms and con-
tributing genes (1,2). In particular, the contribution of each of
several genes to the complex disease state is likely to be
small, and only the joint effect of several susceptibility
genes (often in concert with predisposing environmental
factors) leads to disease, making functional validation of
complex disease-causing genes difficult (3).
Success in identifying causative genes for Mendelian diseases
has raised hopes that such genes can be used as therapeutic tar-
gets for sophisticated new drugs, and that genetic profiling of
affected individuals could improve accuracy of diagnostic and
prognostic information and more effective drug use in the clinic
(4). However, the positional cloning techniques successfully
employed for Mendelian diseases have proved less effective
for complex diseases, and genome-wide and high throughput
techniques are generating ever larger sets of candidate disease
genes for further analysis (5). For example, loci implicated in
susceptibility to multifactorial disease by linkage analysis can
be up to 30 Mb, often containing several hundreds of genes
(6). Comprehensive empirical analysis of so many candidate
genes is prohibitively time-consuming and expensive.
A pertinent role for bioinformatics research exists in the
analysis of biological data for candidate genes, and sub-
sequent selection of a subset of most likely disease gene can-
didates for empirical validation. Many computational
methods have been developed to address this problem, and
existing methodologies mine many different data sources
containing sequence data, biological information, functional
information and expression data for candidate genes. There
is an ever-increasing wealth of such genomic data now
available in public databases (7,8).
A variety of existing computational approaches to selection
of candidate disease genes has been tested, peer-reviewed and
presented independently. We illustrate the combined use of
multiple methods that in principle achieve the same aim in
a fair common ground. Unlike other comparative bioinform-
atics studies, such as the Critical Assessment of protein Struc-
ture Prediction (CASP) comparison of protein modelling
algorithms (9), we do not aim to select a ‘best’ method due
to the difference in focus of the methods presented. Addition-
ally, it is currently impossible to prove that a predicted can-
didate gene is not associated with the disease of interest,
making such an assessment unfeasible. Instead, we identify
the most commonly selected candidate genes.
Because of the different inputs and algorithms used, genes
with less comprehensive annotation may be selected by some
methods and not others, so are not missed in the
overall study. A prospective user presented with an array of
diverse methods and outputs may employ the methods
depending on the data available for their candidate gene list.
In the case study presented here, we prioritize a subset of can-
didate genes according to their selection by multiple methods,
with the premise that these genes are less likely to be artefacts
or false positives due to idiosyncrasies of any single approach.
In this context, we present the independent methods and
what we believe to be a useful illustration of application of
these methods to the analysis of T2D and obesity. This
will help prospective users of these methods to understand
method inputs and outputs, and to select suitable methods
to investigate their disease of interest.
Case study disease: T2D
Our aim is to harness in concert the individual strengths of
the different approaches to provide an accurate, informative
and appropriate selection of candidate disease genes for the
complex disease T2D and the related trait obesity. Diabetes
mellitus is an increasingly common disease with profound
impact on health and longevity, and is estimated by the
World Health Organization to affect more than 150 million
people worldwide. Around 90% of cases are T2D, a disease
closely linked with obesity in which the body is unable to
respond appropriately to insulin produced by the pancreas.
T2D is defined by elevations in plasma glucose levels (hyper-
glycemia), but encompasses a variety of metabolic abnormal-
ities, including reduced responsiveness to insulin (insulin
resistance) in key insulin target tissues such as muscle, adip-
ose tissue, liver, kidney and brain; abnormal accumulation of
lipids in non-adipose tissue, and abnormal pancreatic beta-
cell function leading to insufficient insulin secretion
(10,11). While previously considered a disease of adult life,
T2D is increasingly observed in children and adolescents
(http://www.who.int/topics/diabetes_mellitus/en/), an alarm-
ing trend which may relate to the increasing prevalence of
obesity worldwide.
The contribution of heredity to T2D appears to differ con-
siderably between different populations and in different
environments, consistent with the profile of a complex dis-
ease. While family and twin studies, population studies and
genetic admixture data offer good evidence that heredity
plays an important role (12), it is clear that both pre- and
post-natal environment and lifestyle are critical contributors
to diabetes pathogenesis (13).
Several relatively uncommon monogenic forms of diabetes
have been characterized. These frequently entail defects in
pancreatic b-cells and insulin secretion [e.g. MODY diabetes
(14)] or adipose tissue development [e.g. lipodystrophy syn-
dromes (15)]. These single genetic changes can result in
highly penetrant monogenic diabetes, suggesting that more
subtle genetic changes in these pathways might play a role
in determining susceptibility to T2D (16).
Genome-wide linkage-based approaches and association
studies have been extensively employed in an attempt to
identify T2D susceptibility genes, and some regions of replic-
ated significant linkage have been documented, although con-
sensus on all loci has not been reached (10). To date, the only
candidate susceptibility gene identified by positional cloning
is CAPN10, encoding the protease Calpain 10, and this find-
ing has not been widely replicated [reviewed in Ref. (11)].
Obesity is a significant health burden that affects an
increasingly large proportion of the global population, fre-
quently co-occurs with T2D, and is the main risk factor for
T2D at both individual and entire population levels due to
the link between adiposity, abnormal function of adipocytes
and insulin resistance (17). Susceptibility to obesity is
strongly influenced by multiple genetic factors in addition
to the effects of environmental factors, and causative genes
for this complex disease have proved elusive (18–20).
In our study, we additionally apply computational methods
to the identification of candidate genes for obesity, with the
speculation that co-occurrence of T2D and obesity in such
a large proportion of the affected population may indicate a
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commonality of predisposing genetic background for the two
complex diseases. However, not all obese people develop
T2D, and not all T2D patients are obese. This implies that
we may find a set of genes that are involved with both dis-
eases, and in addition genes that are associated with only
one of the two.
T2D, and the associated disease obesity, offers an appro-
priate case study for a collaborative bioinformatic analysis
of candidate disease genes. Both are high impact diseases
that are reaching epidemic proportions and present a severe
health burden worldwide. There is a vast wealth of clinical
(phenotype) data and positional cloning data available for
T2D in the biomedical literature, and the high co-occurrence
of obesity with T2D allows a possible additional insight as to
genetic background of these related diseases. Finally, extens-
ive research into the genetic causes of T2D has to date yiel-
ded few convincing answers, and we hope that a combined
effort by the bioinformatics disease gene community may
offer some new leads for T2D researchers.
Existing methods
The researchers contributing to this collaboration have
developed, tested and published their methodologies previ-
ously. Here, we provide summaries of these methods with
reference to seminal publications and further information
for each method.
GeneSeeker (http://www.cmbi.ru.nl/geneseeker/) (21,22):
GeneSeeker is a web tool that filters positional candidate dis-
ease genes based on expression and phenotypic data from
both human and mouse. It queries several online databases
directly through the web, guaranteeing that the most recent
data are used at all times and removing the need for local
repositories. In a test using 10 syndromes, GeneSeeker
reduced the candidate gene lists from an average of 163
position-based candidate genes to an average of 22 candidates
based on position and expression or phenotype. Though par-
ticularly well suited for syndromes in which the disease gene
shows altered expression patterns in the affected tissues, it
can also be applied to more complex diseases.
Analysis of candidate gene expression using eVOC annota-
tion (23): This method performs candidate disease gene
selection using the eVOC (a controlled vocabulary for unify-
ing gene expression data) anatomy ontology. It selects can-
didate disease genes according to their expression profiles,
using the eVOC anatomical system ontology as a bridging
vocabulary to integrate clinical and molecular data through
a combination of text- and data-mining. The method first
makes an association between each eVOC anatomy term
and the disease name according to their co-occurrence in
PubMed abstracts, and then ranks the identified anatomy
terms and selects candidate genes annotated with the
top-ranking terms. Candidate disease genes are thus selected
according to their expression profiles within tissues associ-
ated with the disease of interest. In a test of 20 known disease
associated genes, the gene was present in the selected subset
of candidate genes for 19/20 cases (95%), with an average
reduction in size of the candidate gene set to 64.2%
(±10.7%) of the original set size.
Disease Gene Prediction (DGP) (http://cgg.ebi.ac.uk/
services/dgp/) (24): The genes that are already known to be
involved in monogenic hereditary disease have been shown
to follow specific sequence property patterns that would
make them more likely to suffer pathogenic mutations.
Based on these patterns, DGP is able to assign probabilities
to all the genes that indicate their likelihood to mutate solely
based on their sequence properties. In particular, the proper-
ties analysed by DGP are protein length, degree of conserva-
tion, phylogenetic extent and paralogy pattern. The
performance of this method has been assessed previously
on a test dataset by building a model with a part of the
data (learning set: 75%) and testing with the rest (test set:
25%). On average 70% of the disease genes in the test set
were predicted correctly with 67% precision (24). Genes
involved in complex diseases, similarly to monogenic disease
genes, need to have mutations or variations in the gene
sequence that impair or modify the function or expression
of the protein they encode, leading to a disease phenotype.
Thus, we believe that, although DGP has been designed for
the prediction of mendelian diseases, it can also be useful
for the identification of complex-disease genes as it will
identify those genes with higher likelihood of suffering
mutations.
PROSPECTR and SUSPECTS (http://www.genetics.med.
ed.ac.uk/suspects/) (25,26): It can be shown that genes
implicated in disease share certain patterns of sequence
based features like larger gene lengths and broader conserva-
tion through evolution. PROSPECTR is an alternating
decision tree which has been trained to differentiate between
genes likely to be involved in disease and genes unlikely to
be involved in disease. By using sequence-based features
like gene length, protein length and the percent identity of
homologs in other species as input a score (ranging from
0 to 1) can be obtained for any gene of interest. Genes with
scores over a certain threshold, 0.5, are classified as likely to
be involved in some form of human hereditary disease while
genes with scores under that threshold are classified as
unlikely to be involved in disease. The score itself is a meas-
ure of confidence in the classification. PROSPECTR requires
only basic sequence information to classify genes as likely or
unlikely to be involved in disease.
SUSPECTS builds on this by incorporating annotation data
from Gene Ontology (GO), InterPro and expression libraries.
Candidate genes are scored using PROSPECTR and also on
how significantly similar their annotation is to a set of
genes already implicated in the same disorder (the ‘training
set’). This enables SUSPECTS to rank genes according to
the likelihood that they are involved in a particular disorder
rather than human hereditary disease in general. SUSPECTS
leverages the structure of the GO, requiring GO terms to be
closely enough related semantically speaking to be con-
sidered significant (27). As a rank-based system, it requires
potential candidates to share GO terms with other disease
genes to a greater extent than the other genes in the same
region of interest.
Performance of both PROSPECTR and SUSPECTS was
tested separately with a set of oligogenic and complex dis-
orders including Alzheimer’s disease, hypertension, autism
and systemic lupus erythematosus. At least two implicated
genes for each disease were available. For each implicated
gene, a region of interest was created containing the implic-
ated gene itself (the ‘target gene’) and every gene within
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7.5 Mb on either side. On average each region of interest con-
tained 155 genes. Associated training sets were then created
for SUSPECTS containing the remaining implicated genes
for each disorder.
Using PROSPECTR, on average the target gene was in the
top 31.23% of the resulting ranked lists of candidates and in
the top 5% of those lists 20 times out of 156 (13%). In com-
parison, on average the target gene was in the top 12.93% of
the ranked list from SUSPECTS, which took both the region
of interest and the relevant training set as input in each case.
The target gene was in the top 5% of the ranked list 87 times
out of 156 (56%) (25,26).
G2D (http://www.ogic.ca/projects/g2d_2/) (6,28): This
system scores all terms in GO according to their relevance
to each disease starting from MEDLINE queries featuring
the name of the disease. This is done by relating symptoms
to GO terms through chemical compounds, combining
fuzzy binary relations between them previously inferred
from the whole MEDLINE and RefSeq databases. Then, to
identify candidate genes in a given a chromosomal region,
G2D (genes to diseases) performs BLASTX searches (29)
of the region against all the (GO annotated) genes in RefSeq.
All hits in the region with an E-value <10e10 are registered
and sorted according to the GO-score of the RefSeq gene they
hit (the average of the scores of their GO annotations). Note
that hits in the genome might correspond to known or
unknown genes, or to a pseudogene. In a test with 100 dis-
eases chosen at random from OMIM (Online Mendelian
Inheritance in Man) (30), using bands of 30 Mb [the average
size of linkage regions (6)], G2D detected the disease
gene in 87 cases. In 39% of these it was among the best
three candidates, and in 47% among the best 8 candidates
(28).
POCUS (http://www.hgu.mrc.ac.uk/Users/Colin.Semple/)
(31): POCUS exploits the tendency for genes predisposing
to the same disease to have identifiable similarities, such as
shared GO annotation, shared InterPro domains or a similar
expression profile. Therefore where genes within different
susceptibility regions for the same disease share GO or
InterPro annotation and/or are co-expressed, these genes
may be considered good candidates. Although genes may
be selected as candidates on the basis of sharing only a single
GO term or InterPro domain, genes lacking this annotation
completely will not be selected. Some polygenic/complex
diseases may be caused by different genes that are not func-
tionally related. In such cases this method would not be
expected to select the disease genes as candidates, but may
still, by chance, find functional similarities between some
other genes in the regions (especially where there are many
regions or the regions contain many genes). Each observed
similarity between genes in different regions is given a
score. The score is based on the probability of seeing such
specific (or more specific) similarities between genes in
different randomly chosen regions of the genome containing
many genes. Where such a specific (or more specific) simil-
arity would not be seen by chance in >5% of sets of randomly
chosen region analysed, the similar genes are considered to
be good candidates. Therefore in cases where disease genes
are not functionally related (or where there is no data to sug-
gest the disease genes are functionally related) POCUS will
select no candidate genes in 95% of cases. This means that
POCUS is far more conservative than the other methods
discussed. Where many large regions are analysed
almost any similarity between genes in different regions
will have a considerable probability of being seen by chance.
Therefore this method is not likely to be successful when
many large regions are analysed, so analysis should be
restricted to the most tightly defined and best-supported
regions available.
The performance of POCUS was tested by using it to look
for known disease genes. Test susceptibility regions were cre-
ated containing known disease genes and the surrounding
genes (31). Test susceptibility regions were created for 120
diseases for which more than one associated gene appears
in the OMIM database. POCUS was then used to analyse
the set of test regions corresponding to each disease. The per-
formance was measured by the percentage of known disease
genes selected as candidates from the test regions. The
enrichment for disease genes in the selected genes compared
to the whole susceptibility region was also considered.
Enrichment was calculated as Enrichment ¼ (disease genes
selected/non-disease genes selected) / (disease genes in
region/all genes in region). Where the test regions contained
20 genes in total the percentage of disease genes found was
41.7% and enrichment was 10.5-fold. For 100 genes the equi-
valent figures were 25.8% and 36.9, respectively, and for 200
genes 14.9% and 46.3. It is important to note that these results
were obtained with no prior knowledge of disease pathogen-
esis. However, POCUS can also take into account prior
knowledge of the disease, either in the form of known disease
genes or preferred genes that are weighted during the
analysis. Preferred genes could be genes expressed in the
affected tissue or genes selected by other programs as being
likely candidates.
MATERIALS AND METHODS
Collation of the starting set of candidate T2D genes
We use the results of association studies as a primary filter of
all known genes, in a first step in the selection of likely T2D
and obesity candidate genes. We have used all loci clearly
identified by association studies (Table 1) in order to include
all possible likely candidate genes. Genetic loci of candidates
are detailed in Supplementary Table S1, allowing researchers
to focus on their regions of interest. We have selected mul-
tiple genetic loci, designated by cytogenetic band, that have
been implicated in T2D by linkage and association studies,
and are described in the biomedical literature (Table 1).
Our aim is to cover the majority of loci thus associated with
T2D. We have assembled all genes from these regions into
our starting set of candidate genes as defined by Ensembl
(www.ensembl.org, v.31) (Supplementary Table S1). Our
search is focused on finding T2D candidates, and the overlap-
ping set of candidates for both T2D and obesity. This starting
set of 9556 candidate T2D genes has therefore been used as
the same candidate gene set for identifying obesity genes,
under the assumption that any genes that are causative for
both diseases would be represented within the T2D candidate
gene group. We also discuss briefly candidates from this set
that are selected as candidates for obesity only.
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GeneSeeker (21,22)
GeneSeeker was run in batch mode with the following
expression/phenotypic profiles: Obesity: ‘(fat OR adipose
OR hypothalamus OR pituitary OR gut) NOT (eye OR
bone OR skin OR hair)’; T2D: ‘(insulin OR glucose OR pan-
creas OR fat OR adipose OR liver OR kidney OR gut) OR
(muscle AND glucose) NOT (eye OR bone OR skin OR
hair)’. For obesity, hypothalamus and pituitary were included
to allow for hormonal influences. For T2D, the settings were
chosen based on prior knowledge and a brief literature
review. The term ‘brain’ was intentionally left out of the
‘NOT’ section of both queries to avoid spuriously excluding
valid genes that may also be expressed in the brain, given the
broad expression profile of this organ (e.g. the muscle glucose
transporter GLUT4 is also expressed in the brain). House-
keeping genes were not filtered out since glucose metabolism
is a fundamental cellular process. The remaining settings
were left at their defaults (10 cM maximum Oxford-grid
distance, no databases excluded). The resulting candidate
genes were validated against their respective loci using
Ensembl BioMart, since GeneSeeker uses (Oxford-grid)
chromosomal synteny for orthology determination and not
per-gene orthology.
Analysis of candidate gene expression using
eVOC annotation (23)
Association of each eVOC anatomy term with the disease
name is measured according to co-occurrence in PubMed
abstracts, to generate a ‘frequency of association’ value for
each term. The method then determines the frequency with
which each term has been used to annotate genes in the
Ensembl database (www.ensembl.org), to give the ‘frequency
of annotation’ value. The ranking score s is calculated for
each term using these values. Four top-scoring eVOC terms
are selected from the ranked list and these terms are com-
pared with eVOC terms annotated to candidate disease
genes. The system allows one mismatched term between the
terms identified by text-mining and the terms used to annotate
candidate genes. Thus, genes selected as most likely candid-
ates from the candidate gene list are those annotated with at
least three eVOC terms that match the four top-scoring
disease-associated eVOC terms.
DGP (24)
A decision tree-based model was built based on sequence
properties (i.e. protein length, phylogenetic extent, degree
of conservation and paralogy). This model was then applied
to all the genes in the disease loci analysed in order to obtain
a probability score for these proteins to be involved in hered-
itary disease. Note that this probability score is indicative of
the probability of the genes to suffer mutations that impair the
functionality of the protein encoded to cause a disease pheno-
type. It does not assume any particular phenotype and it does
not account for specific phenotype features.
PROSPECTR and SUSPECTS (25,26)
The genes in each locus were scored by SUSPECTS first
using a training set made up of genes already implicated in
obesity and then, separately, using a training set made up
of genes already implicated in T2D (Supplementary Table
S2). The top 10th percentile of each results set was then
taken to represent a group of genes enriched for good candid-
ates. This proportion, providing a balance of sensitivity and
specificity, was chosen on the basis of tests using positive
controls as described in Adie et al. (26). All genes were
also scored by PROSPECTR based on their sequence fea-
tures. Genes with PROSPECTR scores >0.65 (8% of the
total) were selected as possible candidates.
Table 1. Loci associated with T2D through linkage and association studies
Locus Reference
1q21–25 (74–82)
1p31 (83)
2p11 (84)
2p22–2p13 (75,79,85)
2p25 (83)
2q12 (86)
2q24 (87)
2q33–2q37 (81,88–91)
3p12–3p13 (83,92)
3p24-22 (74,84,93)
3p26 (83)
3q11 (75)
3q27–29 (79,87)
4q27–4q28 (74,92,94)
4q32–34 (84,95)
5q13 (82,93)
5q31–5q32 (74,82)
6p21–6p22 (88)
6q12 (75)
6q15–6q27 (74,78,85,96–99)
7p15 (82)
7p21–7p22 (90)
7q22 (78)
7q36 (89)
8p21–8p22 (81,82,87)
8p11–8p12 (81)
8q11 (95)
8q24 (82)
9p13–p24 (84,88,92)
9q31 (78)
9q33 (83)
10p13 (93)
10q23 (82)
10q26 (79,83,92)
11p12–p14 (90,96)
11q23 (78)
12p11 (74)
12q15–12q21 (93,100)
12q24 (85,94,101)
14q11–14q13 (76,83,90)
14q23–14q24 (98)
14q32 (95)
15q11 (86)
15q13–q21 (90)
16p12–16q11 (84,85)
17p13–17q22 (84,85,94)
18p11 (74,75,81,83,86,89)
18q21–18q23 (83,89)
19p13 (94)
19q13 (86)
20p11–20p13 (79,94,95,97,98)
20q12–13 (79,88,90,94,97,102)
Xq23–27.3 (93,98)
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G2D (6,28)
G2D makes predictions of candidates on chromosomal
regions by defining and scoring a number of BLASTX
matches of that region against a scored database of genes.
For the sake of the comparison presented in this work, the
results had to be mapped to genes and not genomic locations,
therefore the BLASTX hits that did not overlap with any cur-
rent ENSEMBL gene prediction were filtered out (these can
be obtained using the G2D web server (6,28) for a particular
genomic region and disease). The final result is an ordered list
of candidates for each chromosomal region and disease with a
score that depends on their GO annotation. We have added a
second score to the candidates, the R-score. This is the relat-
ive score of a sequence according to the distribution of GO
scores of the RefSeq set used to characterize the region (the
sequence ranking according to its GO-score minus one
divided by the total number of sequences in the RefSeq
set). R-score values close to zero indicate a strong possible
relation of the sequence to the disease under consideration
according to the current knowledge. The R-score allows com-
paring candidates for a given disease across different
genomic regions linked to it; that is, one can see for which
of the multiple genomic regions analysed G2D obtained
better candidates (28).
POCUS (31)
The POCUS method is sensitive to noise. The inclusion of
poorly defined susceptibility regions, or regions with a ques-
tionable association with the disease can result in failure to
select similarities between disease genes, as such similarities
are obscured by the background noise (see ‘Existing methods,
POCUS’). Therefore the analysis was confined to the best
supported and most tightly defined regions. These were
3p22–p24, 3q27–q terminal, 10q26, 11p12–p14, 14q11–
14q13, 15q13 and 18q22–p23. Genes scoring above a thresh-
old of 0.95 were considered good candidates. This stringent
threshold is a direct reflection of the degree of statistical sup-
port for the candidate genes returned by POCUS, according to
performance on positive controls (known disease genes) unre-
lated to the present data. At this threshold, spurious, non-
disease genes are expected to be nominated as candidates
for <5% of diseases analysed. Using more liberal thresholds
results in only a small increase in true positives (correctly
identified disease genes) but an accompanying large increase
in false positives (non-disease genes) returned as candidates
by POCUS (31).
Analysis of candidate gene lists generated
For each gene, the methods that select that gene have been
collated. The candidate gene list is sorted by the number of
methods that have selected each gene. The likelihood of
any gene being selected by all seven methods is very small,
as the method POCUS was run on only a subset of the starting
set of candidate genes, and also the extent of annotation of
genes in the initial candidate gene set is highly varied. In
our study, the maximum number of methods that selected a
candidate gene was six out of a total of seven. The most fre-
quently selected genes are ranked as the top group selected by
six of the seven methods (referred to as the 6/7 set), and the
second group is a larger set of genes selected by five out of
the seven methods (referred to as the 5/7 set). The candidates
in the 6/7 set are assessed individually through review of lit-
erature and available data. For the larger groups (the 5/7 set),
we have investigated the pathways in which these genes are
most frequently implicated, and also present an approach to
rank the candidates according to the characteristics of the
methods that select each gene, as described below.
Pathways represented by candidate genes
Mootha et al. (32) studied the regulation of sets of genes in
tissues from diabetic patients. The authors collated groups
of genes that are known to be involved in eleven different
pathways (Table 2, and Supplementary Table S3), in order
to determine in which pathways their sets of genes are most
active (32). We have used this pathway data to identify which
pathways are most commonly represented in our sets of
candidate genes for T2D and obesity, and in the overlapping
set of candidate genes.
Ranking of the 5/7 sets of T2D and obesity
candidate genes
To accommodate the potential bias that is introduced when
several methods utilize very similar data sources and are
therefore more likely to select the same genes, we have
Table 2. Comparison of gene sets selected by 5/7 methods, with pathways defined by Mootha et al. (32)
Pathway with total number
of assigned genes
No. of
genes
T2D % of
gene set
% of
pathway
Obesity % of
gene set
% of
pathway
T2D and
Obesity
% of
gene set
% of
pathway
Fatty acid metabolism 24 1 1.1 4.2 4 3.4 16.7 1 1.7 4.2
Gluconeogenesis 32 3 3.2 9.4 2 1.7 6.3 2 3.4 6.3
Glycolysis 31 1 1.1 3.2 2 1.7 6.5 1 1.7 3.2
Glycogen metabolism 24 2 2.1 8.3 0 0.0 0.0 0 0.0 0.0
Insulin signaling 50 1 1.1 2.0 2 1.7 4.0 1 1.7 2.0
Ketogenesis 9 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
Pyruvate metabolism 435 11 11.7 2.5 16 13.8 3.7 8 13.8 1.8
Reactive oxygen species homeostasis 7 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
Krebbs cycle 16 1 1.1 6.3 1 0.9 6.3 1 1.7 6.3
Oxidative phosphorylation 87 1 1.1 1.1 0 0.0 0.0 0 0.0 0.0
Mitochondria 457 14 14.9 3.1 17 14.7 3.7 9 15.5 2.0
Total Candidate Genes selected 94 116 58
No. of genes, the total number of genes assigned to each pathway; T2D/Obesity, the number of T2D or obesity 5/7 candidates found in this pathway; T2D and
Obesity, the number of genes in common to T2D and obesity found in this pathway; % of gene set, the percentage of T2D and/or obesity candidates that are found in
this pathway; % of pathway, the percentage of total genes assigned to this pathway found in the T2D and/or obesity candidate set.
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developed a system to rank the candidate genes according to
‘which’ methods, rather than simply ‘how many’ methods
have successfully selected them. The input data sources for
each method are defined (Table 3), and for each gene selected
we have counted the total number of independent data
sources that are represented across all methods that select
that gene. Genes with more independent data sources
involved in their selection are thus given a higher ranking.
Additionally, we have taken into consideration the number
of candidate genes that each method has selected: a method
that selects a large percentage of the starting gene set will
have lower weighting than a method that is more selective
and chooses few candidate genes. This weighting is calcu-
lated as the inverse of the fraction of the initial candidate
set that is selected and is averaged across the methods used
to select each gene. A higher score therefore predicts a
more likely candidate:
Score ¼ ðnumber of data sourcesÞ*average
ðtotal genes/selected genesÞ
RESULTS
From the starting set of 9556 genes, each of the methods
selected a subset of most likely candidate genes for T2D
and obesity, ranging in size from 2 to 3046 genes
(Table 3). The selected genes were grouped according to
the number of methods that selected each gene (Supplement-
ary Table S1). Nine genes are selected as potential T2D genes
by 6/7 methods (a summary of these candidate genes is
shown in Table 4). We selected these as our primary candid-
ate gene set, with the premise that genes selected by the most
independent methods are least likely to be false positives or
artefacts of the type of approach used. Four of the nine are
located in the mitochondrion (BCKDHA, OAT, ACAA2,
ECHS1). Some are involved in the metabolism of fatty
acids (ACAA2, ECHS1, LPL), lipids (LPL and ACAA2),
amino acids (BCKDHA and OAT), and glycogen and glucose
(PRKCSH and PGM1). CSF1R is a tyrosine kinase transmem-
brane receptor for the cytokine colony stimulating factor
1 (CSF1), and is involved in macrophage differentiation,
function and production; and TGFBR2 is a Ser/Thr kinase
transmembrane receptor for transforming growth factor-beta
(TGFb), with a role in transcriptional regulation.
A total of five genes are selected as most likely candidate
genes for obesity by 6/7 methods. Two of these, LPL and
BCKDHA, overlap with the set of most likely T2D candid-
ates, and the additional three selected as candidates for obes-
ity only are CAT, NEU1 and VLDLR (Table 4).
Five methods select 94 candidates for T2D and 116 candid-
ates for obesity. Of these, 58 genes are common to both can-
didate sets (Supplementary Table S1).
DISCUSSION
Candidate genes selected by 6/7 methods
Insulin resistance is one of the principal features of T2D that
appears early in the disease state, and is strongly associated
with mitochondrial dysfunction. Defects in muscle and liver
glucose metabolism have been implicated in T2D and insulin
resistance [reviewed in Ref. (33)]. Increasingly, however,
aberrant processing of fatty acids and their metabolites within
the mitochondria has been implicated in the development of
insulin resistance. Defects in fatty acid metabolism may
cause accumulation in the cell of fatty acyl CoAs and diacyl-
glycerol, with subsequent inhibition of insulin-stimulated glu-
cose transport activity leading to insulin resistance [reviewed
in Ref. (33,34)]. In both obesity and T2D, there is a reduction
in glucose oxidation and storage, TCA cycle activity and
b-oxidation and electron transport enzyme activity (35).
Extensive evidence shows that mitochondrial function is
also required for normal glucose-stimulated insulin secretion
from pancreatic b-cells via the production of ATP by oxidat-
ive phosphorylation, thus linking mitochondrial pathways to
another component of diabetes pathology (34,36). Microarray
studies have also shown that expression of nuclear-encoded
mitochondrial genes involved in oxidative phosphorylation
is dysregulated in tissues obtained from both humans with
diabetes (32,37–39), and from mouse models of insulin defi-
cient diabetes (40). Moreover, oxidative phosphorylation
activity and mitochondrial bioenergetic capacity are both
impaired in diabetic humans (41,42). Even in insulin-resistant
but normoglycemic individuals (prediabetes), expression of
oxidative genes and upstream regulators is decreased (39)
Table 3. (A) Sources of input data for each method and (B) number of genes in the starting candidate set, and number of genes selected by each method
Methods
GeneSeeker eVOC system DGP PROSPECTR SUSPECTS G2D POCUS
(A) Input
PubMed abstracts X X X
eVOC annotation X
Sequence data X X X X
GO annotation X X X
Protein data X X X X
Expression libraries X X X
Orthologous mouse genes X
OMIM X
(B) Number of genes selected
Starting set of candidates 9556 9556 9556 9556 9556 9556 562
T2D 642 2504 1174 791 956 N/Aa 2
Obesity 281 3046 1174 791 995 N/Aa 2
aG2D ranks all candidate genes, rather than selecting a subset of candidates.
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and ATP production is reduced by 30% compared with con-
trols (43). T2D does not show exclusively maternal inherit-
ance, and appropriately our studied focused on nuclear-
encoded rather than mitochondrial T2D candidates. Taken
together, these data suggest that mitochondrial dysfunction,
perhaps mediated via changes in nuclear-encoded mitochon-
drial gene expression and/or function, may be an early pheno-
type associated with insulin resistance and diabetes risk.
Thus dysregulated fatty acid metabolism and dysregulation
of the oxidative phosphorylation pathway have been identi-
fied as potential causes of diabetes. Our integrated computa-
tional approach, however, has preferentially identified seven
candidate T2D genes (PRKCSH, PGM1, LPL, ECHS1,
ACAA2, BCKDHA and OAT) that are active in oxidative
metabolic pathways (Figure 1). These pathways contribute
via fatty acid, carbohydrate and amino acid metabolism to
the generation of precursors, such as acyl CoA and acetyl
CoA. These precursors feed into the citric acid cycle, which
subsequently leads into the oxidative phosphorylation
pathway (Figure 1). Dysregulation of the selected genes in
the upstream metabolic pathways may thus be contributing
to the observed reductions in TCA flux and ATP
synthesis (43).
Evidence suggests that circulating cytokines and growth
factors secreted by fat tissue modulate responsiveness of
liver and muscle to insulin (44). TGFBR2 is a Ser/Thr kinase
transmembrane receptor for the growth factor TGFb. It is
intriguing that previous studies have implicated TGFb in dia-
betes, diabetic nephropathy and pancreatic dysfunction, for
example analysis of TGFb gene polymorphisms in a cohort
of Chinese T2D patients has identified the TGFb polymorph-
ism T869C (Leu10Pro) as being associated with diabetic
nephropathy in these T2D patients (45). Similarly, CSF1R
is a tyrosine kinase transmembrane receptor for the CSF1,
and is involved in macrophage differentiation, function and
production. While not previously linked to diabetes, CSF1
is expressed in adipose tissue and is regulated by tumour nec-
rosis factor-a (TNFa,) (46), a cytokine that is expressed in
macrophages and adipose tissue and may contribute to
obesity-associated insulin resistance and diabetes (44,47).
Potential links between macrophages and adipocyte function
are of particular interest in this regard, as macrophage
Table 4. Properties of candidate genes selected by 6/7 methods for both T2D and obesity, for T2D only and for obesity only
Name HUGO ID Ensembl_ID Locus LOD score Disease affiliation Gene function
T2D and obesity
Lipoprotein lipase
precursor
LPL ENSG00000175445 8p21.3 2.55 (73) Hyperlipoproteinemia
type I
Hydrolysis of triglycerides
Branched-chain
alpha-keto acid
dehydrogenase
BCKDHA ENSG00000142046 19q13.2 1.50 (77) Maple syrup urine
disease
Amino acid metabolism
T2D only
Ornithine
aminotransferase
OAT ENSG00000065154 10q26.13 2.88 (83), 1.10 (74),
1.69 (70)
Ornithine
aminotransferase
deficiency.
Amino acid metabolism
Macrophage colony
stimulating factor I
CSF1R ENSG00000182578 5q32 1.22 (73) Myeloid malignancy Receptor for colony
stimulating factor 1,
a cytokine which controls the
production, differentiation,
and function of macrophages.
Glucosidase II beta
subunit precursor
PRKCSH ENSG00000130175 19p13.2 1.81 (85) Polycystic liver
disease
Beta-subunit of
glucosidase II, an N-linked
glycan-processing enzyme
in the endoplasmic reticulum
TGFb receptor type II TGFBR2 ENSG00000163513 3p24.1, 3p22 1.27 (65), 2.20 (75) Colon cancer,
Marfan syndrome
type II
Receptor for TGFb, with a
protein kinase domain that
activates transcription factors
Phospho-glucomutase 1 PGM1 ENSG00000079739 1p31.3 1.50 (74) OMIM 171900 Catalyses the transfer of a
phosphate group between the
1- and 6-positions of glucose.
Acetyl-CoA
acyltransferase 2
ACAA2 ENSG00000167315 18q21.1 2.62 (80), 1.10 (74) OMIM 604770 Mitochondrial fatty acid
metabolism (b-oxidation)
Enoyl-CoA hydratase ECHS1 ENSG00000127884 10q26.3 1.69 (70), 2.88 (83),
1.10 (74)
OMIM 602292 Mitochondrial fatty acid
metabolism (b-oxidation)
Obesity only
Catalase CAT ENSG00000121691 11p13 3.08 (81), 2.89 (87) Acatalasia, Catalysis of hydrogen peroxide
to water and oxygen in the
peroxisome
Sialidase 1 NEU1 ENSG00000184494 6p21.33 2.07 (79) Neuraminidase
deficiency
Cleavage of terminal sialic
acid residues from substrates
such as glycoproteins and
glycolipids in the lysosome
VLDLR VLDLR ENSG00000147852 9p24.2 2.38 (83) OMIM 192977 Transport of triacylglycerol
from the liver to adipose
tissue
3074 Nucleic Acids Research, 2006, Vol. 34, No. 10
infiltration of adipose tissues is common in obesity, and
inflammation is likely to be a key component of insulin res-
istance and diabetes risk (44,48).
The link between malnutrition and immunosuppression is
well recognized, and conversely it appears that overnutrition
and obesity may result in activation of proinflammatory path-
ways. Multiple lines of evidence suggest that such immune
mediators, including TNFa, and by implication CSF1, may
be important regulators of insulin resistance, mitochondrial
function, ectopic lipid storage and beta cell dysfunction—
offering further support for a possible role for CSF1 in
T2D and/or obesity (49–51).
Three genes were selected as likely candidates for obesity
only. Catalase, the product of the CAT gene, acts in the per-
oxisome to convert hydrogen peroxide to water and oxygen,
as critical step in control of reactive oxygen species which
may accumulate in excess with oxidative stress and/or
mitochondrial dysfunction. NEU1 encodes sialidase 1, a
lysosomal enzyme which cleaves terminal sialic acid residues
from substrates, such as glycoproteins and glycolipids. Very
low density lipoprotein (VLDL) is a lipoprotein subclass
assembled in the liver from cholesterol and apolipoproteins,
and carries triglycerides from the liver to adipose tissue.
VLDL levels are shown to be significantly elevated in T2D
patients (52). It is likely that defects in the VLDL receptor
(VLDLR) could disrupt VLDL processing and similarly
contribute to T2D and obesity (53,54). Furthermore, in vivo
studies suggest that abrogated expression of VLDLR can
protect mice from obesity (55).
Some of the identified genes are known to interact, sug-
gesting that they belong to common pathways that are implic-
ated in T2D and adding weight to their selection as most
likely T2D candidate genes. TGFb downregulates LPL
expression via Sp1 and Sp3 transcription factor binding
sites (56), and LPL activation has in turn been found to regu-
late ACAA2 and ECHS1 in a rat model (57). Of interest,
regulation of LPL by PPARg , a well-documented T2D
susceptibility gene, has also been extensively described
(58–60). In addition, a strong relationship exists between
LPL and VLDLR, with direct binding of LPL to VLDLR. LPL
lipolytic activity converts VLDL to smaller particles for
endocytosis by VLDLR, enhancing VLDL binding to the
receptor (53). Coordinated regulation of LPL and VLDLR
expression levels has also been demonstrated in response to
diet, and may contribute to obesity by promoting shunting
of dietary fat from skeletal muscle to adipose tissue (54).
Likewise increased LPL activity increases the propensity
for obesity and insulin-resistance in a mouse model (61,62).
Our methods select LPL and BCKDHA as the most likely
candidates in common for both obesity and T2D. The interac-
tion of LPL with multiple T2D- and obesity-related genes
supports the selection of this candidate for both diseases.
Activity of LPL is central to metabolism of trigylcerides
and fatty acid metabolism, and is associated with VLDLR
and PPARg . To a lesser degree, LPL is associated with regu-
lation of ACAA2 and ECHS1, also identified as potential can-
didates in this study. There is also some evidence that TGFb
interacts with LPL (56,63,64). Of particular interest, a study
by Wang et al. (65) concludes that the lipoprotein lipase
Pvu II polymorphism is significantly associated with coronary
artery disease severity and with type 2 diabetes in coronary
artery disease patients, independent of changes in circulating
lipid levels, and a transgenic mouse study highlights a role for
b-cell-derived LPL in regulation of glucose metabolism and
insulin secretion in pancreatic islets (66). BCKDHA appears
to be less extensively networked (according to current
information), but plays an important role in amino acid meta-
bolism and the processing of a-keto acids in the mitochon-
drion into intermediate molecules for the citric acid cycle.
It is possible that disruption of these pathways might lead
to altered concentrations of intermediates with subsequent
insulin resistance and increase in adipose storage. Microarray
analysis has also shown dysregulated expression of both LPL
and BCKDHA in skeletal muscle of Mexican–American
patients with T2D (39).
Candidate genes selected by 5/7 methods
Five methods select 94 candidates for T2D and 116 for obes-
ity. Of these, 58 genes are common to both candidate sets
(Supplementary Table S1). We analysed these gene sets in
three different ways:
First, we compared these gene lists to the pathway datasets
compiled by Mootha et al. (32) (Supplementary Table S3).
For T2D, obesity and the overlapping candidate sets, the
pathway sets containing the largest number of the 5/7 candid-
ate genes are gluconeogenesis, pyruvate metabolism and
mitochondrial genes. When comparing the percentage of
the genes from each pathway that appear in the candidate
gene sets, the most extensively represented pathway sets
Figure 1. Involvement of candidate T2D genes in cellular metabolism
pathways, selected candidates are shown in red.
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are those of fatty acid metabolism and gluconeogenesis for
T2D, obesity and the overlapping set; glycogen metabolism
for T2D, and glycolysis for obesity and the overlapping can-
didate set (Table 2). As with candidates selected by 6/7 meth-
ods, the genes most commonly represented are those from
processes related to and preceding oxidative phosphorylation,
including processes in the mitochondrion.
Second, we compared the genes selected by 5/7 methods to
candidate T2D genes determined by empirical SNP and
microarray analysis in previous studies (Supplementary
Table S4). In their SNP analysis, Florez et al. (11) identified
three polymorphic genes in common with our T2D and obes-
ity candidates, including PCSK2 and INSR for both diseases
and GYS1 as an additional T2D candidate. In array analyses,
both GYS1 and GPI were dysregulated in skeletal muscle
from humans with T2D (38,39). Again, these genes generally
function in metabolite-processing pathways that lead into
oxidative phosphorylation: GYS1 (muscle glycogen synthase,
ENSG00000104812) has a role in glycogen metabolism and
has been extensively implicated in diabetes (OMIM no.
138570); PCSK2 (neuroendocrine convertase 2 precursor,
ENSG00000125851) encodes a proinsulin-processing
enzyme that plays a key role in regulating insulin biosyn-
thesis (OMIM no. 162151); INSR (ENSG00000171105)
encodes the insulin receptor, the first step in a complex insu-
lin signalling network, and has been implicated in diabetes
(OMIM no. 147670); and GPI (Glucose-6-phosphate iso-
merase, ENSG00000105220) encodes a phosphoglucose iso-
merase protein involved in the glycolytic pathway (OMIM
no. 172400).
Third, an issue for consideration in the analysis of selected
candidate genes is the similarity/dissimilarity in the seven
methods applied in this study. These methods employ an
array of input data types to inform the selection of candidates,
and there is significant overlap in input data type between
some methods, and less between others (Table 3). This intro-
duces potential bias to the selection process: selection of a
candidate gene by several methods using the same input
data types may be less valuable than selection of a candidate
by several methods that use disparate data sources. Equally, a
candidate gene selected as one of a large subset of the candid-
ates carries less weight than a candidate selected as one of a
small subset of candidates. In order to demonstrate how this
type of bias may be accounted for in the analysis of our can-
didate gene sets, we have developed a scoring system that
takes these variables into consideration and ranks the candid-
ate set accordingly. This approach could be of use to a
researcher wishing to determine empirically the involvement
of a subset of genes from the larger 5/7 candidate sets, giving
an approximate rating of the merit of the selected candidates.
The ranked sets of T2D and obesity 5/7 genes list the candid-
ates from most to least likely, depending on the subset of
methods that selected them (Supplementary Table S5)
We have presented an overview of seven independent com-
putational methods for identifying candidate disease genes,
and we have applied them to the analysis of candidate
genes for the complex disease T2D and the related complex
disease obesity. Rather than selecting a ‘best’ method, we
have used the methods to complement each other in selecting
most likely candidates, and to offer the prospective user a bet-
ter understanding of the inputs, outputs and functionality of
each available method. A survey of these methods working
in concert also offers the bioinformatics community an
opportunity to assess the efficacy of current computational
approaches to disease gene identification, and inform future
directions for research. We show here that applying a concert
of computational approaches to finding disease genes can
select genes with functions and characteristics appropriate
Table 5. Analysis of previously proposed T2D and obesity disease genes from loci studied
Symbol Ensembl ID Locus G2D eVOC SUSPECTS DGP GeneSeeker POCUS PROSPECTR Total
T2D
GYS1a ENSG00000104812 19q13 X X X X X 5
IRS1a ENSG00000169047 2q33–2q37 X X 2
CAPN10a ENSG00000142330 2q33–2q37 X 1
LMNAb ENSG00000160789 1q21.2–q21.3 X 1
ENPP1b ENSG00000197594 6q22–q23 X X 2
HNF4Ab ENSG00000101076 20q12–q13.1 X X 2
PRKAB1 (71) ENSG00000111725 12q24 X X X 3
PRKAB2 (71) ENSG00000131791 1q21 X X 2
ATF6 (72) ENSG00000118217 1q23 X X 2
Total 6 5 2 5 2 0 0
Obesity
ACDCa ENSG00000181092 3q27–29 X X X 3
ADRB2a ENSG00000169252 5q31–5q32 X X X 3
ADRB3a ENSG00000188778 8p11–8p12 X X 2
LEPRa ENSG00000116678 1p31 X X X 3
NR3C1a ENSG00000113580 5q31–5q32 X X X X X 5
TNFb(73) ENSG00000111956 6p21.3 X X X 3
APOA4b ENSG00000110244 11q23 X 1
LDLRb ENSG00000130164 19p13.3 X X X X X 5
Total 5 4 4 7 3 0 2
aGenes used in PROSPECTR training set (68–70).
bGenes from the Genetic Association Database, located in regions studied and with more than one independent non-negative association study (http://
geneticassociationdb.nih.gov/).
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to T2D and obesity aetiology, based on the assumption that
novel disease genes may share some characteristics with iden-
tified disease genes (67), and identify pathways that warrant
further investigation. We show that this approach is appropriate
for the investigation of complex disease aetiology due to
selection of multiple most likely disease genes, and can be
used to identify pathways and regulatory networks of aetiolo-
gical significance. In the identification of genes underlying
complex disorders, such as T2D and obesity, the challenge is
to reduce the large lists of candidate genes from genome-
wide studies without discarding the potentially numerous
aetiological genes. However, the majority of ‘known’ disease
genes identified to date that are used to populate artificially
assembled test datasets are for monogenic disorders, and it is
consequently difficult to assess the performance of existing
methods in the complex disease scenario.
The methods we present here have each been previously
rigorously tested independently using such test datasets, and
their performance in these circumstances has been well docu-
mented (22–25,28,31). The logical progression is to apply
such methods to real disease scenarios and identify most
likely candidate genes. These are studies, however, for
which there is no ‘known’ answer, and confirmation of ‘cor-
rect’ candidate selection consequently becomes unfeasible.
Also, most methods generate fairly large lists of most likely
candidates rather than single genes or small subsets. We have
aimed to overcome some of the limitations of these methods
applied in isolation by applying all methods to a single prob-
lem and then comparing the sets of candidate genes selected
by each method. In this way, the genes selected for further
analysis are less likely to be artefacts or false positives result-
ing from the limitations of a single approach.
In this study we have focused on the candidates selected
by the most number of methods as being the most likely
candidates, as discussed below. This approach could also be
used to highlight potential candidates that are selected by a sub-
set of methods and are missed by the other methods, depending
on the type of data available. For example, DGP uses sequence
characteristics to select the candidate gene GATM, which is
involved in amino acid metabolism in the mitochondrion and
would be a sensible candidate gene for T2D: additional annota-
tion of this gene (e.g. GO and eVOC annotation) is not sufficient
for selection by any other methods.
An understanding of the different approaches used allows
us to refine the lists of selected candidates further. For
example, genes selected by G2D are ranked by a scoring sys-
tem that prioritizes most likely candidates according to a cal-
culated R-score (6,28), and by selecting T2D candidates that
are ranked, for example, in the top 1000 genes of the candid-
ate set, we can prioritize five of the nine candidates in order
(from most to least likely: LPL, BCKDHA, PRKCSH,
TGFBR2 and ACAA2) in the 6/7 candidate gene list. Simil-
arly, we can use the R-score to prioritize and order 34/94 can-
didates from the 5/7 candidate set, and for candidate obesity
genes (see Supplementary Table S7).
Our lists of most frequently selected genes (by 6/7 meth-
ods) contain a predominance of genes involved in the
processing of metabolites destined to feed into glycolytic
and mitochondrial oxidative phosphorylation pathways. We
have compared the selected genes with empirical data for
genes dysregulated in T2D, and find some overlap of
pathways and function between the gene sets. Our selected
candidate genes appear to be realistic candidates for a role
in T2D and obesity aetiology.
We have identified a selection of genes that have previ-
ously been proposed as disease genes for T2D (six genes)
and obesity (eight genes) and fall within the loci that we
have analysed (68–73), (http://geneticassociationdb.nih.gov/).
We determine which of these genes are identified as likely
candidates by our cohort of methods (Table 5). From this ana-
lysis, it can be seen that many of the genes have been identi-
fied as candidates by multiple methods (e.g. GYS1 has been
identified by 5/7 methods as a T2D candidate gene, and
NR3C1 and LDLR have been identified by 5/7 methods as
obesity candidate genes). None of these genes have been pro-
ven conclusively to be common T2D or obesity causative
genes, and true positive common disease genes for T2D
and obesity have yet to be unequivocally identified (68–70).
However, ATF6, selected by 2/7 methods, may have a nom-
inal association with T2D in Pima Indians and has been
recommended for further research (72), and TNF was recently
found to be upregulated in morbidly obese T2D patients (73).
Equally, there is no true negative control set: even for char-
acterized candidate genes for which no dysregulation has
been identified in the disease state we are limited by current
knowledge regarding how genes may be dysregulated,
although recent research shows that the candidates PRKAB1
and PRKAB2, selected by 3/7 and 2/7 methods, respectively,
are not associated with T2D (71). Selection of novel genes
outside the ‘known’ set of genes by our methods does not
therefore indicate failure of our approach, as candidate
genes identified for T2D to date have not been convincingly
proven or disproven.
We recognize that prioritizing candidate genes by com-
monality of selection by methods relies on assumptions
that all methods are equally ‘good’ and that they perform
with equivalent specificity and sensitivity. These assumptions
may introduce bias to our selected gene sets. Some methods
have significant overlap with other methods in their input
data, and output in terms of the number of candidate genes
selected from a common starting set can vary greatly accord-
ing to method. For example, a gene that has been extensively
studied for a long time will have a large amount of associated
literature and has a better chance of being selected by all
methods that use PubMed abstracts as a datasource. Genes
that have well-characterized protein products are more likely
to be selected by methods that access InterPro data on protein
domains, or genes that are ubiquitously expressed are more
likely to be identified as good candidates by methods that
rely on gene expression data. Even among methods that
mine overlapping sources of data, there may be subtle differ-
ences in the way data are used and combined with other
sources which can affect the bias introduced by multiple
methods; for example POCUS mines GO terms shared
between different genetic loci whereas G2D deduces associ-
ations between symptoms and GO terms from MEDLINE
through an annotated protein database (RefSeq).
Thus a candidate selected by two methods with very
diverse data inputs may carry more weight than a candidate
selected by two methods using the same input data; and a
gene belonging to a large subset of selected candidates will
carry less weight than a member of a much smaller candidate
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subset. In our primary set of most likely T2D candidates,
selected by 6/7 methods, the impact of this set size and
input data bias are minimal because all candidates were selec-
ted by the same subset of six methods, so are equally biased
with regard to input data sources and size of candidate sets
selected. Also, with the small numbers of candidates in
these sets it is possible to consider each candidate gene inde-
pendently and in greater detail. However, in the larger 5/7
sets, this bias has been taken into consideration and we
have described an approach for approximate ranking of
these candidate gene sets according to the similarities and
dissimilarities of their selection methods. We have also
described the metabolic pathways that are most commonly
represented in the candidate sets, and finally compared the
5/7 candidate genes with those previously identified by
microarray analysis as dysregulated in T2D patient samples.
Further potential for bias in computational approaches to
disease gene selection arises from the varying extent of
gene annotation and available data for genes in the starting
set of candidates. This is particularly evident when the start-
ing set of candidate genes has been compiled according to
locus: each locus contains genes across the full spectrum
from totally uncharacterized to well characterized and annot-
ated. The greater the extent of annotated data for a given can-
didate gene, the more likely it is to be selected by data-
mining techniques. This could be the explanation for the
high prevalence of disease-associated genes selected in the
6/7 candidate set (Table 4): previously identified disease
genes are likely to be well studied and consequently extens-
ively annotated. In contrast, a very recently identified gene
has less associated literature and annotation, and is less likely
to be selected by these methods regardless of its suitability.
This is balanced to some extent, however, by the methods
that use gene sequence data input, including DGP and PRO-
SPECTR, regardless of additional gene annotation. G2D also
uses the raw genomic sequence as input, and a gene can be
detected as a candidate even if it has not been previously
characterized. Moreover, while it is true that it will tend to
point to functions/features already associated with the disease
in the literature, it can also point to relations never made
before in an explicit way. This is again illustrative of the
strength of using all methods in a complementary fashion
to balance each other’s capacities.
The methods select diverse gene sets according to their
different input data and analyses, and use existing genetic
data to propose novel disease gene candidates. Even for the
method SUSPECTS, which uses these proposed candidate
genes within a training set, other genes were selected as
more appropriate due to novel interpretation of the existing
data. Each method has been previously rigorously tested within
the limits of current knowledge for well characterized diseases,
and there is no way to know whether T2D candidates will fol-
low the same general ‘rules’ as for other diseases. The nature
of the bioinformatics approach is to generate likely candidates
by extensive analysis of known characteristics of genes, and is
inevitably restricted by existing information be it GO annota-
tion, current expression data or DNA sequence. However we
show here that existing information can be synthesized to
select novel candidates, and this is the aim of our methods.
We do not seek to prove that these are true disease genes—
this can only be undertaken empirically.
We believe it is important to progress from intellectual analysis
of individual bioinformatics disease gene identification
approaches using artificially assembled test datasets, to applica-
tion of these techniques in the most appropriate way to real
and pressing disease scenarios; and this has been the aim of
our collaboration. By making such a transition with a collaborat-
ive and focused effort, using a concert of complementary meth-
ods, we hope to generate new, appropriate leads from existing
data to assist researchers in prioritizing candidate disease genes
for further empirical analysis.
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